Optimization of a Dihydropyrrolopyrazole Series of Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors: Discovery of an Orally Bioavailable Transforming Growth Factor-β Receptor Type I Inhibitor as Antitumor Agent
Journal of Medicinal Chemistry2008Vol. 51(7), pp. 2302–2306
Citations Over TimeTop 11% of 2008 papers
Hongyu Li, William T. McMillen, Charles R. Heap, Denis McCann, Lei Yan, Robert M. Campbell, Sreenivasa R. Mundla, Chi-Hsin R. King, Elizabeth A. Dierks, Bryan D. Anderson, Karen S. Britt, Karen Huss, Matthew D. Voss, Yan Wang, David K. Clawson, Jonathan M. Yingling, J. Scott Sawyer
Abstract
In our continuing effort to expand the SAR of the quinoline domain of dihydropyrrolopyrazole series, we have discovered compound 15d, which demonstrated the antitumor efficacy with oral bioavailability. This effort also demonstrated that the PK/PD in vivo target inhibition paradigm is an effective approach to assess potential for antitumor efficacy. The dihydropyrrolopyrazole inhibitor 15d (LY2109761) is representative of a novel series of antitumor agents.
Related Papers
- → Identification of the metabolites of benzo[f]quinoline and benzo[h]-quinoline formed by rat liver homogenate(1983)11 cited
- Synthesis of Mercaptoalkoxy quinoline Compounds(2002)
- → Synthesis of benzo[g]quinoline derivatives(1970)
- → Carcinogenic Activity of Analogues of <italic>p</italic>-Dimethylaminoazobenzene. IV. Activity of the Quinoline Analogues<xref ref-type="fn" rid="FN1">2</xref>(1961)